drugset / Trial / NCT02843321

Combined Infusion of Cytotoxic T-Lymphocytes and Vaccination

NCT02843321 ↗

Phase 1 Unknown 12 enrolled University of Sydney
NaSingle-groupOpen-labelTreatment

Summary

To assess the safety and biological efficacy of prophylactically administered donor-derived multi-infection specific cytotoxic T lymphocytes (CTLs) (targeting cytomegalovirus (CMV), Adenovirus (Adv), Epstein Barr virus (EBV), Varicella-Zoster virus (VZV), Influenza (Flu), BK virus (BKV), and Aspergillus (Asp)) combined with early immunisation with Influenza and VZV vaccines for the prevention of viral and fungal infection following allogeneic blood or marrow stem cell transplantation.

Timeline

Start
2012-08
Primary completion
2017-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Donor derived infection-specific T-cells Cell therapy — —
Subject Fluvax Vaccine — —